|
Jun 4
|
Vera Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
|
|
Jun 3
|
Vera Therapeutics Announces Refinancing of Existing Oxford Debt Facility, Providing up to $500 Million of Term Loans
|
|
Jun 3
|
Why Vera Therapeutics, Inc. (VERA) Skyrocketed On Monday
|
|
Jun 2
|
Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA Nephropathy
|
|
Nov 8
|
Vera Therapeutics to Participate at Upcoming Investor Conferences
|
|
Nov 7
|
Vera Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results
|
|
Oct 2
|
Vera Therapeutics Announces Expanded Atacicept Development Program In Multiple Autoimmune Kidney Diseases
|
|
Oct 2
|
Vera Therapeutics Announces Late-Breaking Oral Presentation of ORIGIN Phase 2b Long-term Results at the American Society of Nephrology Kidney Week 2024
|
|
Sep 26
|
Is Vera Therapeutics Inc. (VERA) the Best Performing Small-Cap Stock in 2024?
|
|
Aug 29
|
Vera Therapeutics to Participate at September Investor Conferences
|
|
May 9
|
Vera Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
|
|
May 7
|
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
May 6
|
Vera Therapeutics, Inc.'s (NASDAQ:VERA) high institutional ownership speaks for itself as stock continues to impress, up 5.0% over last week
|
|
Apr 23
|
Health Care Roundup: Market Talk
|
|
Apr 13
|
Could This Stock Be the Next Biotech Buyout?
|
|
Apr 12
|
Insider Sells at Vera Therapeutics Inc: SVP, Finance, Chief Accounting Officer Joseph Young ...
|
|
Apr 11
|
Vertex Pharmaceuticals to buy Alpine Immune Sciences in $4.9B deal
|
|
Apr 5
|
ARS Pharmaceuticals, Nuvalent, and More Stocks See Action From Activist Investors
|
|
Apr 2
|
Vera Therapeutics Announces Two Oral Presentations at the 61st European Renal Association Congress
|
|
Mar 20
|
Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
|